Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 5, pp 1265–1275 | Cite as

Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials

  • Yong Yu
  • Xun Xu
  • Ziyan Du
  • Minhua ShiEmail author
Original Article

Abstract

Purpose

The aim was to compare the efficacy and toxicity of gemcitabine plus docetaxel (GD) with platinum-based regimens in patients with untreated advanced non-small cell lung cancer (NSCLC).

Methods

We searched PubMed, Embase and the Cochrane Central Register of Controlled Trials databases for relevant trials. Reference lists of original articles and review articles were also examined. Abstracts presented at the ASCO and ESMO meetings were also searched. Studies were evaluated for eligibility and quality, and then, the data were extracted and analyzed. Statistical analyses were conducted by using RevMan 5.1. The primary end point was overall survival (OS). Secondary end points included 1-year survival, time to progression (TTP), overall response rate (ORR) and grade 3–4 toxicity.

Results

Nine randomized controlled trials were identified ultimately. The meta-analysis demonstrated that the survival between GD and platinum-based regimens was comparable according to the pooled HR for overall survival (1.04, 95% CI = 0.96–1.12, p = 0.39) and RR for one-year survival (0.94, 95% CI = 0.84–1.06, p = 0.33). Platinum-based regimens had an advantage in TTP (HR = 1.12, 95% CI = 1.02–1.24, p = 0.02) and ORR (RR = 0.86, 95% CI = 0.74–0.99, p = 0.03). However, GD induced less grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia (RR = 0.36, 95% CI = 0.15–0.86, p = 0.02; RR = 0.35, 95% CI = 0.23–0.53, p = 0.00; RR = 0.68, 95% CI = 0.52–0.88, p = 0.003; RR = 0.53, 95% CI = 0.34–0.82, p = 0.004, respectively). Grade 3–4 diarrhea, sensory neuropathy, fatigue and thrombocytopenia were comparable between the two groups.

Conclusions

GD acquired similar survival with platinum-based regimens in first-line treatment of advanced NSCLC. Platinum-based regimens had an advantage in TTP and ORR with more grade 3–4 nausea/vomiting, anemia, neutropenia and febrile neutropenia compared with GD.

Keywords

Carcinoma Non-small cell lung Gemcitabine Docetaxel Platinum Cisplatin Carboplatin 

Notes

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence this work.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer, Part 1: early-stage disease. Oncology (Williston Park) 17:357–364Google Scholar
  3. 3.
    Azzoli CG, Baker SJ, Temin S et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266PubMedCrossRefGoogle Scholar
  4. 4.
    NCCN Non-Small Cell Lung Cancer Panel Members (2011) Non-small cell lung cancer. NCCN clinical practice guidelines in oncology version 3, 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
  5. 5.
    Pujol JL, Breton JL, Gervais R et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610PubMedCrossRefGoogle Scholar
  6. 6.
    Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945PubMedCrossRefGoogle Scholar
  7. 7.
    Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484PubMedCrossRefGoogle Scholar
  8. 8.
    Julian PT Higgins, Douglas G Altman, Jonathan AC Sterne (2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (ed) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org
  9. 9.
    Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRefGoogle Scholar
  10. 10.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  11. 11.
    Rubio JC, Estevez SV, Rivera FV et al (2006) Gemcitabine/Docetaxel (GD) vs Gemcitabine/Cisplatin (GC) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no. 18S (June 20 Supplement): 17017Google Scholar
  12. 12.
    Rubio JC, Estevez SV, Rivera FV et al (2006) A randomized phase IIB trial of gemcitabine and cisplatin (GC) versus gemcitabine and docetaxel (GD) in stage IIIB/IV advanced non-small cell lung cancer (NSCLC). an galician lung cancer group study. ESMO annual meeting abstract 2006. 751PGoogle Scholar
  13. 13.
    Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: Similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571–576PubMedCrossRefGoogle Scholar
  14. 14.
    Takiguchi Y, Katakami N, Yoshimori K et al (2004) Docetaxel in combination with either cisplatin (DC) or gemcitabine (DG) in unresectable non-small cell lung carcinoma (NSCLC): a randomized phase II study by the Japan lung cancer cooperative clinical study group. EMSO annual meeting abstract 2004. 635PDGoogle Scholar
  15. 15.
    Georgoulias V, Ardavanis A, Tsiafaki X et al (2004) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. ESMO annual meeting abstract 2004, 637PDGoogle Scholar
  16. 16.
    Binder D, Beinert T, Schweisfurth H et al (2004) Docetaxel-gemcitabine versus cisplatin-gemcitabine plus sequential docetaxel in the first-line treatment of metastatic non-small cell lung cancer (NSCLC): interim results of a randomized Phase II trial. ESMO Ann Meet Abstr 2004:7071Google Scholar
  17. 17.
    Binder D, Sailer V, Schweigert M et al (2002) A randomized phase II study of gemcitabine/docetaxel vs gemcitabine/cisplatin followed by docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002Google Scholar
  18. 18.
    Kakolyris S, Tsiafaki X, Agelidou A et al (2002) Preliminary results of a multicentre randomised phase III trial of docetaxel plus gemcitabine (DG) versus vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer [abstract]. In: Proceedings of the American Society of Clinical Oncology 2002Google Scholar
  19. 19.
    Georgoulias V, Samonis G, Papadakis E et al (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47–S51PubMedCrossRefGoogle Scholar
  20. 20.
    Georgoulias V, Papadakis E, Alexopoulos A et al (1999) Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: a preliminary analysis of a multicenter randomized phase II trial. ASCO annual meeting abstract 1999, Abstract No:1778Google Scholar
  21. 21.
    Novello S, Falcone A, Crino L et al (2009) Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer 66:327–332PubMedCrossRefGoogle Scholar
  22. 22.
    Rubio JC, Vazquez S, Vazquez F et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379–384PubMedCrossRefGoogle Scholar
  23. 23.
    Rigas JR, Carey M, Dragnev KH et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): Subgroup analysis from D0112. J Clin Oncol 26: May 20 suppl, abstr 8100Google Scholar
  24. 24.
    Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143–150PubMedCrossRefGoogle Scholar
  25. 25.
    Katakami N, Takiguchi Y, Yoshimori K et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan lung cancer cooperative clinical study group. J Thorac Oncol 1:447–453PubMedCrossRefGoogle Scholar
  26. 26.
    Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results. J Clin Oncol 2006 ASCO annual meeting proceedings part I, vol 24, no 18S (June 20 Supplement): 17116Google Scholar
  27. 27.
    Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  28. 28.
    Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845–853PubMedCrossRefGoogle Scholar
  29. 29.
    D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):116–119CrossRefGoogle Scholar
  30. 30.
    D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936PubMedCrossRefGoogle Scholar
  31. 31.
    Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Department of Respiratory MedicineThe Second Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations